Carisma Therapeutics (NASDAQ:CARM – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.
Institutional & Insider Ownership
44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Carisma Therapeutics and NewAmsterdam Pharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Carisma Therapeutics | $10.77 million | 0.02 | -$60.48 million | $0.73 | 0.01 |
| NewAmsterdam Pharma | $22.50 million | 186.62 | -$203.82 million | ($1.79) | -20.07 |
Carisma Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Carisma Therapeutics has a beta of -9.34, suggesting that its share price is 1,034% less volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Carisma Therapeutics and NewAmsterdam Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Carisma Therapeutics | 1 | 0 | 1 | 1 | 2.67 |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 18,081.82%. NewAmsterdam Pharma has a consensus target price of $49.00, indicating a potential upside of 36.41%. Given Carisma Therapeutics’ higher probable upside, equities analysts clearly believe Carisma Therapeutics is more favorable than NewAmsterdam Pharma.
Profitability
This table compares Carisma Therapeutics and NewAmsterdam Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Carisma Therapeutics | -254.28% | N/A | -192.17% |
| NewAmsterdam Pharma | -943.23% | -26.49% | -24.37% |
Summary
NewAmsterdam Pharma beats Carisma Therapeutics on 8 of the 14 factors compared between the two stocks.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
